MITSUBISHI-HEAVY-IND
18.4.2019 09:23:11 CEST | Business Wire | Press release
Premiering for the first time in the world, Mitsubishi Heavy Industries Thermal Systems, Ltd., a Group company of Mitsubishi Heavy Industries, Ltd. (MHI) (TOKYO: 7011), is adopting R454C, a refrigerant with an extremely low global warming potential (GWP), in a 1-horsepower (HP) class residential air-conditioner. The conventional shortcomings of the R454C,for example; inferior heat exchanger performance attributable to it being a mixed refrigerant have been overcome through the use of proprietary technology that optimize the heat exchanger’s flow volume and other measures. The company has already developed a demonstration unit of the residential air-conditioner featuring R454C and preparations are underway towards mass production with an eye on an initial launch into the European market, where environmental regulations are particularly stringent.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190418005241/en/
The R454C refrigerant has an ozone depletion potential (ODP) of 0 (zero) and a GWP of 146 (CO2 =1). The latter value is approximately 1/14th and 1/5th the respective GWP levels of refrigerants currently and most widely used in air-conditioners of small/medium scale: R410A (2090) and R32 (675). The overall global warming impact (GWP x refrigerant volume) from the demonstration unit’s refrigerant represents a 91.3% reduction from the level of MHI Thermal Systems’ previous model for the European market*1 .
Worldwide initiatives aimed at stopping global warming were strengthened in October 2016 with the adoption of the “Kigali Amendment” to the Montreal Protocol on Substances that Deplete the Ozone Layer. Named after the capital city of Rwanda where the delegates met, the Kigali Amendment mandates progressive reduction in hydrofluorocarbons (HFC), substances that do not deplete the ozone but do adversely impact global warming*2 . In addition, since 2015 the member nations of the European Union (EU), where environmental awareness is deeply entrenched, have gradually expanded regulations affecting the sale and usage of substances, including HFCs, that have GWP values of 150 and higher, contributing to global warming. MHI Thermal Systems’ development of the world’s first small-capacity residential air-conditioner adopting the R454C refrigerant is thus a leading and positive response to these international movements.
Going forward, MHI Thermal Systems will continue to dedicate its resources to developing and marketing high-performance products using low-GWP refrigerants, thereby contributing to protection of the global environment in markets everywhere.
|
Notes |
||||
|
*1: |
The top-of-the-line SRK25ZSX-S with a piping length of 5m, which adopts the R410A refrigerant |
|||
|
*2: |
These substances are subject to the terms of both the Montreal Protocol (1987) and the preceding Vienna Convention for the Protection of the Ozone Layer (1985). |
|||
About Mitsubishi Heavy Industries Group
Mitsubishi Heavy Industries, Ltd. (MHI), headquartered in Tokyo, is one
of the world’s leading industrial firms with 80,000 group employees and
annual consolidated revenues of around 38 billion U.S. dollars. For more
than 130 years, the company has channeled big thinking into innovative
and integrated solutions that move the world forward. MHI owns a unique
business portfolio covering land, sea, sky and even space. MHI delivers
innovative and integrated solutions across a wide range of industries
from commercial aviation and transportation to power plants and gas
turbines, and from machinery and infrastructure to integrated defense
and space systems.
For more information, please visit MHI’s
website: www.mhi.com/index.html
For
Technology, Trends and Tangents, visit MHI’s new online media SPECTRA
:
spectra.mhi.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190418005241/en/
Contact:
PRESS CONTACT: Corporate Communication Department Mitsubishi Heavy Industries, Ltd. James Bennett, +81-(0)3-6275-6200 Email: mediacontact_global@mhi.co.jp
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom